A n estimated 390 000 out-of-hospital cardiac arrests 1 and 200 000 in-hospital cardiac arrests 2 occur annually in the United States. Although survival to hospital discharge remains low despite considerable efforts (overall: 11% of those treated by Emergency Medical Services personnel), 3 outcomes have improved for the past 10 years compared with prior decades. [4] [5] [6] [7] In the Get with the Guidelines-Resuscitation registry, risk-adjusted survival for in-hospital cardiac arrest improved from 13.7% in 2000 to 22 .3% in 2009. 5 Similarly, in the Cardiac Arrest Registry to Enhance Survival, risk-adjusted survival rates for out-of-hospital cardiac arrests improved from 5.7% in 2005 to 8.3% in 2012. 6 Improvement in survival could be attributed to the development of an organized concept of postcardiac arrest care 8 that includes application of several innovative therapies and technologies, including percutaneous coronary intervention, antiarrhythmic medication, hemodynamic support, therapeutic hypothermia, metabolic stabilization, and ventilator support. [9] [10] [11] Although cardiac arrest research has focused on survival, the financial burden of postcardiac arrest care and its health care-associated cost are unknown. Moreover, it is unclear whether hospital profiles or use of specific therapeutic interventions linked with survival are associated with cost burden. To address these gaps in knowledge, we aimed to estimate the total health care cost associated with postcardiac arrest hospitalizations. We also examined the secular trends of inflation-adjusted cost and its association with patient and hospital level characteristics and implementation of certain therapeutic interventions.
METHODS

Data Source
The US Nationwide Inpatient Sample (NIS) is a part of the Healthcare Cost and Utilization Project, sponsored by the Agency for Healthcare Research and Quality. The data are publically available to any researcher for purposes of reproducing the results. NIS is a large all-payer publicly available database of inpatient stays that contains discharge level data from ≈8 million hospitalizations from ≈1000 hospitals
WHAT IS KNOWN?
• In the United States, survival after cardiac arrest has improved as compared with prior decades, but the financial burden of postcardiac arrest care remains largely unknown.
WHAT THE STUDY ADDS?
• We observed that the inflation-adjusted cost associated with index hospitalization after cardiac arrest increased progressively over time adjusting for secular trends. Although the costs increased across all strata of length of stay, it increased even more for patients with longer hospital admissions. Use of cardiovascular interventions and devices and certain hospital characteristics were the main contributors of rising cost.
• The health care cost associated with the index hospitalization after cardiac arrest represents an increasing financial burden on the US health care system. One estimate places the total cost of outof-hospital cardiac arrest in the United States at $33 billion/y, and this study suggests that 17% of that total figure is attributable to index hospitalization postcardiac arrest. Although targeted cost containment for postarrest interventions may reduce the finance burden, the potential economic impact of funding research into prediction and prevention of cardiac arrest offers a greater potential societal benefit, both economically and clinically. 
Study Population
We used the ICD-9-CM code 427.5 to identify all hospital admissions associated with the principal or secondary diagnosis of cardiac arrest from 2003 to 2012 and included patient outcomes of either in-hospital death or discharge alive, independent of neurological function. We obtained patient demographics and hospital-level data, and the latter includes size based on bed numbers (small, medium, and large), location/teaching status (rural, urban nonteaching, and urban teaching), and geographic region (Northeast, Midwest, South, and West). The definition of these designations is further described by Healthcare Cost and Utilization Project. [12] [13] [14] [15] [16] [17] We used the Agency for Healthcare Research and Quality comorbidity software to retrieve baseline comorbidities for each patient. We also used ICD-9-CM codes to assess for baseline comorbidities not included in the Agency for Healthcare Research and Quality software (Table I in the Data Supplement). These included history of myocardial infarction, coronary artery disease, dyslipidemia, and atrial fibrillation. We also assessed the use of selected cardiovascular interventions using Current Procedure Terminology codes previously reported in the literature (Table II in 
Study End point
The primary end point of this study was logarithmic transformation of inflation-adjusted hospital cost for index hospitalization after cardiac arrest. The NIS collects hospital charges, which is the amount the hospital billed for services. Total hospital charges were converted to hospital costs using Healthcare Cost and Utilization Project Costto-Charge Ratios based on cost information obtained from hospital accounting reports that were collected by the Centers for Medicare and Medicaid Services. Hospital costs reflects the actual expenses incurred for hospital services, such as wages, supplies, and utility costs. Annual costs were adjusted for inflation by using the consumer price index inflation multiplier released by the US Bureau of Labor with 2012 as the base year.
Statistical Analysis
Using survey analysis methods, we used hospital-level discharge weights provided by the NIS to estimate the number of hospitalizations after cardiac arrest. We acquired baseline demographics, baseline comorbidities, hospital characteristics, and selected cardiovascular interventions. We calculated weighted frequencies and percentages to present categorical variables. We also presented continuous variables as weighted means and SDs. We used Poisson regression to assess trend over time. To adjust for hospital clustering, we used mixed effect generalized linear regression to assess the effect of independent predictors of inflation-adjusted hospital cost. The variation in cost was reasonably explained by the model (coefficient of determination=0.569), and procedural variables improved the model fit. All statistical analyses were performed using SAS version 9.4 (SAS institute Inc, Cary, NC). We considered P<0.05 as significant and all tests were 2 sided. To avoid common errors in the study design, we followed the checklist developed by Khera and Krumholz 18 to adhere to best research practices and appropriate use of this large administrative database (Box I in the Data Supplement). 19 This study was exempt from full institutional review board review because it publically available and without patient identifiers.
RESULTS
We identified 291 792 unique encounters who were admitted for (or developed) cardiac arrest during their index hospitalization from 2003 to 2012. The number of weighted hospital admissions for that period was 1 387 396. The mean age of the cohort was 66 years, 45% were women, and 68% were white (Table 1) . Medicare and Medicaid were the primary payer of 72% of these patients while 20% had private insurance. Approximately 75% of the admissions occurred during weekdays, with one quarter during the weekend. Of these admissions (n=1.387 million), 31% were in the lower 25th percentile of the median household income and 19% were above the 75th percentile. Large hospitals admitted 66% of patients presenting with cardiac arrest, and most these admissions were in urban hospital systems. Of these hospitals, 16% were in the Northeast region, 22% in the Midwest, 41% in the South region, and 21% in the Western region.
There was no noticeable change in patient and hospital characteristics across the study period. Of the encounters who presented with cardiac arrest, 18% had dyslipidemia, 24% had diabetes mellitus, and 44% had hypertension (Table 2 ). Approximately 30% of the patients had coronary artery disease, 5.5% had prior myocardial infarction, and 22% had congestive heart failure. The prevalence of dyslipidemia, diabetes mellitus, hypertension, and coronary artery disease significantly increased during the study period. However, the prevalence of congestive heart failure and valvular heart disease noticeably decreased over time.
Coronary angiography was performed on 15% of patients, and coronary angioplasty was performed in 7% (Table 3) . There were small, but significant, increase in the use of most cardiovascular procedures but not for permanent mechanical support devices or automatic implantable cardioverter defibrillators. Although therapeutic hypothermia was performed in only 1% of these admissions, the use of hypothermia increased over time. Among all hospital admissions, the use of pacemakers and implantable cardioverter defibrillators was 6% and 3%, respectively. Pacemaker implantation in cardiac arrest patients who survived hospital admission was 10.6%. No significant change in the use of these devices was seen over the study period. Survival †Represents % of total population included in the study; ICD-9-CM code 427.5 was used to identify all hospital admissions associated with primary or any secondary diagnoses of cardiac arrest.
‡P<0.05 were considered significant; P values for linear trends using Poisson regression. §Statistics, except the first row, were weighted summaries, based on probability sampling methods, so they may approximate national statistics.
after cardiac arrest improved over time; however, the mean hospital length remained constant (≈9 days; Table  III in the Data Supplement) . Hospital charges and inflation-adjusted cost significantly increased throughout the study period (Figure 1) . Nonsurvivors had significant increase in hospital charges but not inflation-adjusted cost (Figures 2 and  3) . When stratifying by length of stay, inflation-adjusted cost were higher with longer hospital stays (Figure 4 ; Figure I in the Data Supplement). Costs were significantly increased throughout the study period regardless of hospital lengths of stay. The inflation-adjusted charges and costs had a negatively skewed distribution, and logarithmic transformation was used for multivariable analysis, which had a normal bell-curve distribution. After risk adjustment, increasing age, female sex, and white race were associated with lower rates of inflation-adjusted hospital cost (Table 4) . Hospitalizations of postcardiac arrest patients covered by Medicare were associated with higher costs compared with other health insurance coverage. Lengths of stay at hospitals with large and medium bed numbers were associated with greater cost than hospitals with small bed size. Similarly, urban hospital stays cost more than rural counterparts. Compared with hospitals located in the Northeast, Western region hospitals costs were significantly higher while Southern hospitals had significantly lower cost.
Baseline comorbidities had different effects on inflation-adjusted hospital costs. Notably, prior myocardial infarction, primary diagnosis of myocardial infarction, and hypertension were associated with lower costs. Conversely, congestive heart failure, atrial fibrillation, and electrolyte/fluid imbalances significantly increased cost. Hospitalizations with increased use of cardiovascular interventions were associated with significantly higher hospital cost. Extracorporeal membrane oxygenation, coronary angiography, and implantable cardioverter defibrillators and pacemaker placement were associated with the greatest increase in cost. Of note, patients receiving therapeutic hypothermia had one fourth increased cost compared with admissions without the use of therapeutic hypothermia. Adjusting for patients' demographics, comorbidities, hospital-level characteristics, length of stay, and secular trends, there was an 88% increase in cost ($) for patients who received any cardiovascular procedure during index admission compared with those who did CAD indicates coronary artery disease; MI, myocardial infarction; and NIS Nationwide Inpatient Sample. *Statistics, except the first row, were weighted summaries, based on probability sampling methods, so they may approximate national statistics. †Percent may not add to 100 because of rounding. ‡P<0.05 were considered significant; P values for linear trends.
not. The presence of uncomplicated diabetes mellitus and depression was associated with cost savings. When sudden death was restricted to only primary or first secondary diagnoses, the results from the multivariable regression model were similar (Table IV in 
DISCUSSION
In this study, we analyzed the temporal pattern of health care cost for hospitalizations associated with cardiac arrest in the United States from 2003 to 2012. We also presented the effect of patient comorbidity profile, use of cardiovascular interventions/devices, and hospital characteristics associated with these admissions on hospital cost. We observed that the inflation-adjusted cost associated with hospitalizations in survivors of cardiac arrest consistently increased throughout the study period, regardless of the length of hospital stay. However, hospital cost was stable for those who did not survive the index hospitalization. Patient profiles varied over the study period, and the comorbidities that were associated with greatest increase in cost were history of atrial fibrillation and fluid/electrolyte imbalances. Use of cardiovascular interventions and devices remained stable over time, and they were consistently associated with significant increase in health care cost. We also identified large bed size hospitals, urban teaching hospitals, and Western hospitals as significant contributors to health care expenditure.
We observed a rise in hospital costs over the study period. This observation held even after adjusting for length of hospital stay, survival status, and extensive patient and hospital-level contributors of cost, which further highlights the economic burden of cardiac arrest. This may be partially explained by several factors. First, the complexity of patients with cardiac arrest and multiple chronic conditions may be associated with higher use of hospital resources that we were not able to capture with data available to us in the NIS sample (eg, use of dedicated coronary care units, neuroimaging, or renal replacement therapies). Second, the growing adoption of electronic medical records may have increased the accuracy of billing during the later years of the study. Accordingly, this may also have reflected an increase in captured billing and hospital charges. The patient profile showed increased prevalence of medical comorbidities including conventional cardiovascular disease risk factors, such as hypertension, diabetes mellitus, dyslipidemia, and obesity. We also observed a decrease in the prevalence of congestive heart disease and valvular heart disease. Despite the changing prevalence of these chronic conditions, it is worth noting that patient comorbidity profile had relatively small effect on hospital cost. In fact, only atrial fibrillation and fluid/electrolyte imbalances were associated with increase in cost >10%. This may, at least in part, reflect the accumulating experience in management of these chronic conditions as well as the national effort to adhere with therapies associated with improved outcome. This may have decreased hospital length of stay and in turn associated hospital cost. We also identified use of cardiovascular interventions and devices as major contributors to health care cost. The increased cost may be attributed to use of higher level of care and specialized personnel to perform these cardiovascular procedures and to operate specialized devices, in addition to the cost of devices themselves. These cardiovascular interventions and the use of devices may represent reasonable potential for targeted interventions to contain cost, with standardization of care processes and possible regionalization of these services. It is worth noting that our analyses only address health care costs associated with the hospitalization, and it is reasonable to assume that with increased use of these advanced treatments, downstream cost benefits will be perceived with reduced length of hospitalization, use of intermediate facilities, and reduction in readmission.
We also observed noticeable differences in expenditure by hospital characteristics. Larger hospitals, as well as urban teaching hospitals, were associated with higher cost. This may, at least in part, be attributed to the more medically complex patients, socioeconomic mix of the patient population, and the availability of certain advanced treatments in these centers compared with their counterparts. 8 We also observed regional variation in cost with highest resource use in Western hospitals. In a recent national study assessing regional variation of health outcomes of in-hospital cardiac arrest, there was significant differences in the discharge disposition and use of postdischarge resources across the United States. 20 Therefore, regional differences in costs may partly be because of variation in use of acute versus postacute services. It should be noted that the analysis includes a sizable number of patients who had <1 day length of stay. Whether these patients were indeed survivors of cardiac arrest or they were dead on arrival cannot be ascertained.
Our study has several important limitations. First, we used the NIS, which is an administrative claim data set that depends on ICD-9-CM. Such data sets are prone to coding errors, coding differences across providers and institutions, and change in coding pattern over time. In this study, a potential problem is the inaccuracy of ICD-9 code to identify true cardiac arrest patients or the distinction between out-of-hospital and in-hospital cardiac arrests. Many Emergency Medical Services-defined cardiac arrest, which would be used to determine 427.5 code for hospital admission, turn out not be cardiac in the first place (ie, stroke, sepsis, heart failure, or respiratory failure). Although the coding may not be optimal, this methodology to identify patients with cardiac arrest has been frequently used in prior studies on cardiac arrest, 4, [21] [22] [23] and it has been proposed that more specific coding of cardiac arrest variants be developed for future iterations of ICD coding. 24 Second, a limitation of work such as this is the lack of clinical details on the precise mechanism of the arrest, clinical features before the arrest, the details of the responses to cardiac arrest (such as bystander cardiopulmonary resuscitation and automated external defibrillator deployment), and the level of neurological and cardiovascular disability associated with the arrest. Clearly, this information is relevant to clinical outcomes data, but the economic burden for society is based on cumulative effects. The latter supports the notion of increasing research support for prediction and prevention of cardiac arrest. 8, 25 For example, in the years 2003 to 2004 and 2011 to 2012, the estimated annual inflation-adjusted cost postcardiac arrest in the United States was $7.3 and $11.1 billion, respectively. The ability of health outcomes research to reduce the incidence of cardiac arrest by 10% (2011-2012) would have saved the health care system ≈$1.2 billion. Third, we were not able to ascertain the appropriateness of use of various cardiovascular interventions and devices in patients resuscitated from cardiac arrest, and we were only able to assess the effect of hospital characteristics available to us. As such, we may have missed important systemic patterns associated with cost that may represent valid targets for cost containment interventions. It is possible that other causes for emergency admissions, such as those for pneumonia, stroke, sepsis, and ST-segment-elevation myocardial infarction, could account for the rising health care costs, which was attributed to sudden cardiac arrest in this study. Fourth, because of the large sample size, this study has an enormous statistical power (1-ß), that is able to detect subtle differences in cost. The interpretation of some of these statistically significant results with low strengths of associations may be somewhat challenging. However, patientor hospital-level characteristics with large strength of association remain important predictor of in-hospital cost after cardiac arrest. Finally, it is also important to note that the study population, which included any inpatient with a ICD-9-CM code of 427.5, did not distinguish between out-of-hospital from in-hospital cardiac arrest. The literature has largely studied these separately, and the costs for these events are likely to be substantially different.
In conclusion, hospitalization associated with resuscitated cardiac arrest showed consistent increase in hospital cost for the period of 2003 to 2012. Use of cardiovascular interventions and devices and certain hospital characteristics were the main contributors of rising cost. Postcardiac arrest hospitalizations represent significant impact burden on health care cost. One estimate places the total cost of cardiac arrest in the United States at $33 billion/y, 26 and our data suggests that 17% of that total figure is attributable to index hospitalization postcardiac arrest with and without survival. Future studies are required to identify targeted interventions best associated with survival outcomes and lowest cost, in addition to supporting the potential economic value of funding research into prediction and prevention of cardiac arrest and sudden cardiac death. 25 
